What's Happening?
Latham & Watkins LLP has provided legal counsel to Alkeus Pharmaceuticals in its acquisition by Tarsus Pharmaceuticals, Inc. The agreement, dated July 31, 2026, involves Tarsus acquiring Alkeus, a biotechnology company focused on retinal diseases, particularly
through its development of gildeuretinol (ALK-001), an investigational oral therapy for Stargardt disease. The legal team from Latham & Watkins was led by partners Scott Shean, Andrew Clark, and Shannon Cheng, with support from associates across various specialties including benefits, tax, intellectual property, regulatory, and healthcare matters. This acquisition is part of Tarsus's strategy to expand its portfolio in the field of ophthalmology.
Why It's Important?
This acquisition is significant as it represents a strategic expansion for Tarsus Pharmaceuticals into the retinal disease market, potentially enhancing its product offerings and market position. For Alkeus Pharmaceuticals, the acquisition provides an opportunity to leverage Tarsus's resources and expertise to advance the development and commercialization of its lead product, gildeuretinol. The transaction underscores the ongoing consolidation in the biotechnology sector, where companies are seeking to bolster their pipelines and capabilities through strategic acquisitions. This move could have implications for stakeholders in the pharmaceutical industry, including investors, healthcare providers, and patients, particularly those affected by retinal diseases.
